Patents by Inventor Ralph T. Doyle, Jr.

Ralph T. Doyle, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Statin and omega-3 fatty acids for reduction of Apo-B levels
    Patent number: 8871800
    Abstract: Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: October 28, 2014
    Assignee: GlaxoSmithKline, LLC
    Inventors: Roelof M. L. Rongen, Robert A. Shalwitz, Douglas Kling, Ralph T. Doyle, Jr.
  • OMEGA-3 FATTY ACIDS FOR REDUCTION OF LP-PLA2 LEVELS
    Publication number: 20110251275
    Abstract: Methods are provided for utilizing omega-3 fatty acids, or a combination of a dyslipidemic agent and omega-3 fatty acids, for the reduction of lipoprotein-associated phospholipase A2 (Lp-PLA2) levels. The methods are especially useful in the treatment of patients with primary hypercholesterolemia or hypertriglyceridemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of major adverse cardiovascular events (MACE), major coronary events (MCE), particularly myocardial infarction (MI), revascularizations and ischemic stroke.
    Type: Application
    Filed: January 10, 2011
    Publication date: October 13, 2011
    Inventors: Roelof M.L. Rongen, Douglas Kling, Ralph T. Doyle, JR., Robert A. Shalwitz
  • Treating metabolic syndrome with fenofibrate
    Patent number: 8026281
    Abstract: A method of treating metabolic syndrome in a human diagnosed with metabolic syndrome by administering a therapeutically effective amount of fenofibrate over a treatment period. The results can include identifying a human as not having clinical metabolic syndrome after treatment, as compared to having metabolic syndrome before treatment.
    Type: Grant
    Filed: April 22, 2005
    Date of Patent: September 27, 2011
    Assignee: Lupin Atlantis Holdings, S.A.
    Inventors: Ralph T. Doyle, Jr., Douglas F. Kling, Roelof M. L. Rongen, Keith S. Rotenberg
  • STATIN AND OMEGA-3 FATTY ACIDS FOR REDUCTION OF APO-B LEVELS
    Publication number: 20100010026
    Abstract: Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.
    Type: Application
    Filed: September 17, 2009
    Publication date: January 14, 2010
    Inventors: Roelof M.L. RONGEN, Robert A. SHALWITZ, Douglas KLING, Ralph T. DOYLE, JR.